Geographic Atrophy

Avacincaptad pegol shows significant reduction in GA lesion growth over two years

Izervay (avacincaptad pegol intravitreal solution; Astellas Pharma) demonstrated positive results in the GATHER2 Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), according to data presented at AAO 2023. The study showed that Izervay, administered either every month or every-other-month, significantly reduced...